Naloxone Reversal of Morphine- and Morphine-6-Glucuronide-induced Respiratory Depression in Healthy Volunteers: A Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling Study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Opioid-induced respiratory depression is antagonized effectively by the competitive opioid receptor antagonist naloxone. However, to fully understand the complex opioid agonist-antagonist interaction, the effects of various naloxone doses on morphine and morphine-6-glucuronide (M6G)-induced respiratory depression were studied in healthy volunteers. Methods: Twenty-four subjects received 0.15 mg/kg morphine intravenously at t = 0 followed by placebo, 200 or 400 microg naloxone at t = 30 min. Thirty-two subjects received 0.3 mg/kg M6G intravenously at t = 0 followed by placebo, 25, 100, or 400 microg naloxone at t = 55 min. There were a total of 8 subjects per treatment group. Respiration was measured on a breath-to-breath basis at constant end-tidal Pco2. A mechanism-based pharmacokinetic-pharmacodynamic model consisting of a part describing biophase equilibration and a part describing receptor association-dissociation kinetics was used to analyze the data. Results: Naloxone reversal of M6G-induced respiratory depression developed more slowly than reversal of the respiratory effect of morphine. A simulation study revealed that this was related to the slower receptor association-dissociation kinetics of M6G (koff M6G = 0.0327 +/- 0.00455 min versus morphine 0.138 +/- 0.0148 min; values are typical +/-SE). Duration of naloxone reversal was longer for M6G. This was related to the three- to fourfold greater potency of naloxone as an antagonist against M6G compared with morphine. Increasing the naloxone dose had no effect on the speed of reversal, but it did extend reversal duration. Conclusions: Naloxone reversal of the opioid effect is dependent on the receptor association-dissociation kinetics of the opioid that needs reversal with respect to the rate of reversal. The pharmacodynamics of naloxone determines reversal magnitude and duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence, reversal, and prevention of opioid-induced respiratory depression
Dahan, A., Aarts, L., & Smith, T. W. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181c38c25 · Cited by 634
Self-citation
Cited by
Naloxone dosage for opioid reversal: current evidence and clinical implications
Rzasa Lynn, R., & Galinkin, J. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617744161 · Cited by 346
Algera, M. H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts, L., Dahan, A., & Olofsen, E. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.023 · Cited by 123
Self-citationReducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review
Kim, H. K., & Nelson, L. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1037274 · Cited by 116
Treatment of opioid overdose: current approaches and recent advances
Britch, S. C., & Walsh, S. L. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06125-5 · Cited by 96
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Saari, T. I., Strang, J., & Dale, O. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01355-6 · Cited by 77
Metadata
- Authors
- Olofsen, E., van Dorp, E., Teppema, L., Aarts, L., Smith, T. W., Dahan, A., & Sarton, E.
- Venue
- Anesthesiology
- Published
- 2010-06-01
- Volume
- 112
- Issue
- 6
- Pages
- 1417-1427
- ISSN
- 0003-3022 (ISSN-L)
- OpenAlex
- W1986273848
- Cited by
- 72
- References
- 1
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naloxone Reversal of Morphine- and Morphine-6-Glucuronide-induced Respiratory Depression in Healthy Volunteers: A Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling Study. https://app.cochat.ai/papers/10.1097/aln.0b013e3181d5e29d
- The paper
- Olofsen, E., van Dorp, E., Teppema, L., Aarts, L., Smith, T. W., Dahan, A., & Sarton, E. (2010). Naloxone Reversal of Morphine- and Morphine-6-Glucuronide-induced Respiratory Depression in Healthy Volunteers: A Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling Study. Anesthesiology. https://doi.org/10.1097/aln.0b013e3181d5e29d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.